Business Model Breakdown
How Twist Bioscience Corp Makes Money
TWST
Market Cap
$2.9B
Annual Revenue
$377M
Profit Margin
-19.6%
Employees
979
The Short Version
Twist Bioscience manufactures and sells custom synthetic DNA products and services, acting as a foundational technology provider for the rapidly expanding synthetic biology, genomics, and biopharma industries. They utilize a proprietary silicon-based DNA synthesis platform to produce high-quality, custom DNA sequences, genes, and oligo pools at unprecedented scale and cost-efficiency. This enables researchers, pharmaceutical companies, and other industries to accelerate R&D in areas like drug discovery, diagnostics, sustainable chemicals, and even next-generation data storage, providing the fundamental building blocks of biology.
Where the Revenue Comes From
Gene Synthesis Products (Primary revenue stream)
Next-Generation Sequencing (NGS) Preparation Tools
Antibody Discovery and Biopharma Solutions
DNA Data Storage Services (Emerging revenue stream with long-term potential)
Who buys: Pharmaceutical and biotechnology companies, academic and government research institutions, industrial chemical companies, agricultural firms, and emerging technology companies in DNA data storage.
Why It Works (Competitive Advantages)
- ✔Proprietary silicon-based DNA synthesis platform offering high throughput, accuracy, and cost efficiency.
- ✔Broad product portfolio catering to diverse applications in genomics, drug discovery, and emerging fields.
- ✔Significant intellectual property (IP) protecting their core technology.
Economic Moat: Narrow (Intangible Assets/IP, Cost Advantages, Switching Costs)
What Our Analysis Says
DVR Score as of April 13, 2026
Twist Bioscience (TWST) continues to be a high-risk, high-reward investment with significant 10x growth potential within 3-5 years. The company's unique silicon-based DNA synthesis platform maintains its position for future market leadership in synthetic biology and DNA data storage. Recent Q1 fiscal 2026 results showed robust revenue growth (17% YoY), an improved gross margin (52.0%), and narrowed net losses. Management's raised FY2026 revenue guidance to $435–440 million, coupled with the stated path to adjusted EBITDA breakeven by late FY2026 and positive free cash flow in early 2026, significantly de-risks prior profitability concerns. New product launches and strategic agreements bolster the long-term vision. While still unprofitable, the accelerating financial progress and strategic execution confirm substantial upside potential in a rapidly expanding market, justifying a slightly increased score as these positive trends are further cemented.